Could a nerve drug tame POTS? new trial tests pyridostigmine
NCT ID NCT00409435
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether pyridostigmine, a drug that affects nerve signals, can reduce symptoms of postural tachycardia syndrome (POTS) like rapid heartbeat and dizziness. Fifty adults with POTS will take either pyridostigmine or a placebo for three days. The study aims to see if the drug improves symptom scores and stabilizes heart rate during tilt-table testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pyridostigmine
- What this could lead to
- If it works, this could point toward a short-term treatment to ease POTS symptoms like rapid heartbeat and dizziness.
- What could go wrong
- This is a small, early-phase trial with only 50 people and a 3-day treatment period, so results may not apply broadly or last long.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTURAL TACHYCARDIA SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could ear nerve stimulation calm racing hearts in POTS?
- Can CO2 calm POTS? small study investigates
- Could antibodies be behind POTS? new study investigates
- Could POTS be an autoimmune disease? new study tests nerve stimulation as a treatment
- Could a blood pressure pill calm racing hearts in POTS?
- POTS patients may get relief from blood pressure drug, early study hints